Breaking Down Ardelyx: 4 Analysts Share Their Views

Comments
Loading...

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Ardelyx ARDX in the last three months.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 0 3 0 0
Last 30D 0 0 1 0 0
1M Ago 0 0 1 0 0
2M Ago 1 0 1 0 0
3M Ago 0 0 0 0 0

The 12-month price targets, analyzed by analysts, offer insights with an average target of $6.75, a high estimate of $8.00, and a low estimate of $5.50. A negative shift in sentiment is evident as analysts have decreased the average price target by 6.9%.

price target chart

Exploring Analyst Ratings: An In-Depth Overview

A clear picture of Ardelyx's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Ed Arce HC Wainwright & Co. Maintains Neutral $5.50 $5.50
Christopher Raymond Piper Sandler Raises Neutral $8.00 $7.00
Ed Arce HC Wainwright & Co. Maintains Neutral $5.50 $5.50
Chris Howerton Jefferies Lowers Buy $8.00 $11.00

Key Insights:

  • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ardelyx. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ardelyx compared to the broader market.
  • Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ardelyx's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Ardelyx analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know Ardelyx Better

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

Ardelyx: A Financial Overview

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: Ardelyx's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 74.21%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Ardelyx's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.82% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Ardelyx's ROE stands out, surpassing industry averages. With an impressive ROE of -0.53%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Ardelyx's ROA stands out, surpassing industry averages. With an impressive ROA of -0.23%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: With a high debt-to-equity ratio of 0.66, Ardelyx faces challenges in effectively managing its debt levels, indicating potential financial strain.

The Significance of Analyst Ratings Explained

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In: